HUTCHMED has announced the completion of patient enrollment in a Phase II trial for fanregratinib (HMPL-453), aimed at treating intrahepatic cholangiocarcinoma (IHCC) patients with FGFR2 fusion ...

Additionally, with the growing demand for chronic disease treatments and the ageing baby boomer population, the infusion market is set for significant growth. According to the market research ...

The research delves into how mutations in FGFR2 and FGFR3 affect mandibular bone formation and endochondral bone repair following non-stabilized fractures. The findings reveal that FGFR ...

Post the infusion, core liquidity, taking into account banking system liquidity along with government cash balances, will remain in a "comfortable surplus" of 1.6 trillion rupees by March-end from ...

NEW YORK – Hutchmed on Thursday said it has completed enrollment of a Phase II trial in China testing the FGFR1/2/3 inhibitor fanregratinib in patients with advanced intrahepatic cholangiocarcinoma ...

This fundamental article significantly advances our understanding of FGF signalling, and in particular, highlights the complex modifications affecting this pathway. The evidence for the authors' ...

aDepartment of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, Milan, 20072, Italy bMedical Oncology and Hematology Unit, Humanitas Cancer Center, IRCCS ...

Endoscopic augmentation of the lower oesophageal sphincter using hydrogel implants for the treatment of gastro-oesophageal reflux disease IPG222 27 June 2007 27 June 2007 Carmustine implants and ...